Hansa Biopharma Files IND for New Autoimmune Therapy
The company aims to begin clinical trials for a rapid-acting enzyme to treat Guillain-Barré syndrome.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies are doing enough to develop new treatments for rare diseases?
Hansa Biopharma has submitted an Investigational New Drug (IND) application to the FDA for HNSA-5487, a therapeutic enzyme targeting Guillain-Barré syndrome. The submission follows a Phase 1 study where the candidate demonstrated significant antibody depletion in healthy volunteers.
Why it matters
This application marks a step toward clinical evaluation for a novel IgG-cleaving treatment designed to address urgent unmet medical needs in autoimmune conditions. The therapy aims to provide rapid intervention, potentially shifting current management standards for acute neurological diseases.
In a Phase 1 study of 36 healthy volunteers, HNSA-5487 achieved an IgG reduction of more than 95% within a few hours. This performance is currently being transitioned from initial volunteer testing to clinical development for disease-specific applications.
The players
Hansa Biopharma
A Swedish biotechnology firm focused on developing IgG-cleaving enzymes to treat autoimmune diseases and transplant-related conditions.
US Food and Drug Administration
The federal agency responsible for overseeing the safety and clinical progression of new drug applications in the United States.
The details
HNSA-5487 functions as an IgG-cleaving enzyme, a biological catalyst that breaks down immunoglobulin G, which is the most abundant antibody in human blood. By rapidly cleaving these antibodies, the drug aims to stop the autoimmune attack characteristic of Guillain-Barré syndrome. In the Phase 1 study, the enzyme was delivered via intravenous infusion, a method that introduces the treatment directly into the bloodstream for systemic action.
Timeline
October 20, 2026: Hansa Biopharma submitted the IND application to the FDA.
The Tech Race
This submission marks the latest expansion of Hansa Biopharma's IgG-cleaving enzyme platform into the neurological space. It follows a research trajectory aiming to secure approval for rapidly neutralizing autoimmune triggers across varied severe disease states.
Patients with Guillain-Barré syndrome do not have immediate access to this therapy as it remains in the pre-clinical transition stage. Future access will depend on the successful completion of planned Phase 2a single ascending dose studies and subsequent pivotal trials.
The takeaway
The company plans to initiate a Phase 2a single ascending dose study followed by a pivotal trial to determine the drug's therapeutic viability. Observers should track the FDA's response to the IND filing to confirm the timeline for these forthcoming clinical investigations.
Further reading
Explore the evolving landscape of enzymatic therapeutics in our Biotech section.
Live Poll
Do you believe pharmaceutical companies are doing enough to develop new treatments for rare diseases?
